Exploring bias in platelet P2Y1 signalling: Host defence versus haemostasis
Dingxin Pan1, Graham Ladds2, Khondaker Miraz Rahman3
1Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK.
British Journal of Pharmacology
|July 13, 2023
Summary
Platelets have distinct activation pathways for hemostasis and inflammation. Understanding P2Y1 receptor signaling differences could lead to targeted therapies for inflammatory diseases while preserving normal blood clotting.
Area of Science:
- * Platelet biology
- * Immunology
- * Molecular pharmacology
Background:
- * Platelets are crucial for hemostasis and play a role in inflammation.
- * Platelet activation can contribute to pathological inflammation, sometimes without affecting hemostasis.
- * Distinct activation pathways exist for platelet functions in hemostasis versus inflammation.
Purpose of the Study:
- * To elucidate the differential signaling pathways of platelet activation.
- * To explore the role of the P2Y1 receptor in inflammation and hemostasis.
- * To understand how biased agonism at P2Y1 receptors influences platelet function.
Main Methods:
- * Review of current understanding of P2Y1 receptor structure and signaling.
- * Analysis of distinct platelet activation pathways (Rho-GTPase vs. PLCβ).
- * Consideration of biased agonism by endogenous nucleotides.
Main Results:
- * P2Y1 receptor stimulation is vital for platelet thrombi in hemostasis.
- * P2Y1 receptor activation also drives inflammation, independent of hemostatic changes.
- * Rho-GTPase signaling, not PLCβ, is key for P2Y1-mediated inflammation.
Conclusions:
- * Platelet activation pathways differ significantly between hemostasis and inflammation.
- * P2Y1 receptor signaling exhibits pathway bias depending on the agonist.
- * Targeting these distinct pathways offers potential for therapeutic control of inflammation without compromising hemostasis.
Related Concept Videos
Formation of the Platelet Plug
6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
566
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
566
Introduction to Hemostasis
8.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.4K
Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Disorders of Hemostasis
999
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
999


